Clinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public by merging with a Cormorant-sponsored SPAC. The combined company will continue developing drugs targeting various forms of mutated KRAS proteins that drive cancers.
The post BridgeBio Oncology to Go Public in SPAC Deal Bringing $450M+ for Trio of Cancer Drugs appeared first on MedCity News.
